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sensitivity in vitro and in vivo: is this effect linked to inhibition of angiogenesis?  
P. A. Coucke, E. Cottin 
Laboratory of Radiobiology, CHUV-Lausanne 
Purpose: To investigate in vitro and in vivo the association of SR4233, FMdC and 
irradiation on a WiDr colon cancer cell line and xenograft model. To determine the effect 
of FMdC and SR4233 on VEGF by RT-PCR and Western blot. 
Materials and methods: Clonogenic assays in oxygenated and hypoxic conditions to test 
radiosensitizing capacity of FMdC and/or SR4233. Xenografts of WiDr implanted in Swiss 
nude mice to test the effect on growth delay after irradiation. Semi-quantitative 
investigation of VEGF-mRNA by RT-PCR and VEGF protein by western blotting in vitro on 
ECV cell line. 
Results: In anoxic conditions FMdC looses it's radiosensitizing effect in vitro. The 
combined effect of FMdC and SR4233 results in major increase of radiosenistivity of WiDr 
cells in hypoxic conditions compared to FMdC alone. In vivo, the post-irradiation growth 
delay increases significantly by using the combination FMdC and SR4233 as compared to 
each compound alone. The evaluation of the effects of FMdC and SR4233 on the VEGF-
mRNA and VEGF protein are currently under investigation on a human endothelial cell 
line (ECV), and data will be presented at the meeting. 
Conclusion: FMdC looses it's capacity to sensitize WiDr cells in anoxic conditions; 
however, in these hypoxic conditions the combination of FMdC and SR4233 results in 
significant increase of radiation induced cell kill, highlighting the potential of combining a 
compound with anti-angiogenic effects to a biorecductive drug.  
 
